9LB Stock Overview
A clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 9LB from our risk checks.
Legend Biotech Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$37.80 |
| 52 Week High | US$69.50 |
| 52 Week Low | US$36.20 |
| Beta | 0.12 |
| 1 Month Change | -9.57% |
| 3 Month Change | -40.94% |
| 1 Year Change | -35.93% |
| 3 Year Change | 18.13% |
| 5 Year Change | n/a |
| Change since IPO | 57.50% |
Recent News & Updates
Recent updates
Shareholder Returns
| 9LB | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -8.7% | -3.5% | -0.4% |
| 1Y | -35.9% | -36.9% | 8.6% |
Return vs Industry: 9LB exceeded the German Biotechs industry which returned -36.9% over the past year.
Return vs Market: 9LB underperformed the German Market which returned 8.6% over the past year.
Price Volatility
| 9LB volatility | |
|---|---|
| 9LB Average Weekly Movement | 5.8% |
| Biotechs Industry Average Movement | 6.0% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 9LB's share price has been volatile over the past 3 months.
Volatility Over Time: 9LB's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 2,000 | Ying Huang | www.legendbiotech.com |
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel.
Legend Biotech Corporation Fundamentals Summary
| 9LB fundamental statistics | |
|---|---|
| Market cap | €6.95b |
| Earnings (TTM) | -€428.95m |
| Revenue (TTM) | €315.58m |
22.0x
P/S Ratio-16.2x
P/E RatioIs 9LB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 9LB income statement (TTM) | |
|---|---|
| Revenue | US$342.80m |
| Cost of Revenue | US$561.63m |
| Gross Profit | -US$218.83m |
| Other Expenses | US$247.11m |
| Earnings | -US$465.95m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.56 |
| Gross Margin | -63.84% |
| Net Profit Margin | -135.92% |
| Debt/Equity Ratio | 24.6% |
How did 9LB perform over the long term?
See historical performance and comparison